State of New Jersey
Department of Health
Governor Phil Murphy · Lt. Governor Tahesha Way
Improving Health Through Leadership and Innovation
This dashboard uses interactive data visualizations to display opioid and other drug-related overdose indicators for public health practitioners, researchers, policy-makers, and the public. Data for these indicators were obtained from multiple sources, including the Department of Health, the Division of Consumer Affairs, the Office of the Attorney General and other law enforcement bodies. Explore the dashboard to learn about the opioid epidemic and other drug-related indicators.
The New Jersey Department of Health is committed to supporting communities in preventing fatal overdose. Below, you can find health information and resources for services and supplies to prevent overdose. If you or a loved one needs naloxone, click here for a list of pharmacies with access to free naloxone. You can also text/call 1-877-4NARCAN or click here to obtain a naloxone kit anonymously, for free, through the mail.
New Resource: FY21 Overdose Fatality Review Teams Annual Report
Narcan is a medication used to block the effects of opioids during an overdose. It is important to seek professional medical assistance after administering Narcan because multiple doses may be needed if overdose symptoms return.
This dashboard displays emergency department visits and inpatient hospitalizations caused by non-fatal acute poisonings due to the effects of drugs, regardless of intent.
Death data comes from the Office of the Chief State Medical Examiner. It includes drug mentions in drug-related overdose deaths suspected overdoses by county of incidence.
The New Jersey Prescription Monitoring Program (PMP) is a statewide database that tracks controlled dangerous substances and human growth hormones dispensed in outpatient settings in NJ and out-of-state pharmacies dispensing into NJ. This tool can be used to reduce prescription drug misuse and diversion by allowing providers to view patients’ prescribing histories prior to prescribing medications.
Neonatal abstinence syndrome (NAS) occurs in a newborn who was exposed to certain substances while in the womb. NAS is most commonly associated with opioids, such as heroin, oxycodone, methadone, and buprenorphine.
Hepatitis B and C are viruses that are found in the blood and are spread person to person. These viruses spread mainly when blood and other body fluids infected with the hepatitis virus enters the body of a person who is not infected. The most common routes of transmission for hepatitis B and C include sharing needles, syringes and drug equipment; being born to an infected mother; or having sexual contact with an infected person. The data presented in this dashboard are from the Communicable Disease Reporting and Surveillance System (CDRSS) and includes both acute and chronic hepatitis B and C. Viral hepatitis data is also available on the NJDOH Communicable Disease Service website and on the New Jersey State Health Assessment Data website.
Treatment statistics are derived from the New Jersey Substance Abuse Monitoring System (NJSAMS) of the Division of Mental Health and Addiction Services (DHMAS). NJSAMS contains administrative data on clients who receive substance use treatment in New Jersey and is used by all licensed substance use treatment providers in New Jersey.
